Collin DSilva - Bruker Pres Division
| BRKR Stock | USD 75.61 1.64 2.12% |
Insider
Collin DSilva is Pres Division of Bruker
| Age | 67 |
| Address | 40 Manning Road, Billerica, MA, United States, 01821 |
| Phone | 978 663 3660 |
| Web | https://www.bruker.com |
Bruker Management Efficiency
The company has return on total asset (ROA) of 0.0661 % which means that it generated a profit of $0.0661 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3029 %, meaning that it created $0.3029 on every $100 dollars invested by stockholders. Bruker's management efficiency ratios could be used to measure how well Bruker manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Bruker's Return On Tangible Assets are relatively stable compared to the past year. As of 05/28/2024, Return On Assets is likely to grow to 0.11, while Return On Capital Employed is likely to drop 0.09. At this time, Bruker's Return On Tangible Assets are relatively stable compared to the past year. As of 05/28/2024, Intangibles To Total Assets is likely to grow to 0.23, while Intangible Assets are likely to drop slightly above 196.5 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sandra Eayrs | Nuwellis | N/A | |
| William MBA | STRATA Skin Sciences | 58 | |
| Kevin MD | INVO Bioscience | 65 | |
| Richard Ginn | Tenon Medical | 58 | |
| Laurent Duhoux | Nuwellis | N/A | |
| Michael Goodman | STRATA Skin Sciences | N/A | |
| William MD | Nuwellis | N/A | |
| Christopher Yamamoto | Bioventus | N/A | |
| Mark MD | Bluejay Diagnostics | N/A | |
| Jeff Welch | Bioventus | N/A | |
| Andrea Goren | INVO Bioscience | 57 | |
| Alessandraa Pavesio | Bioventus | 57 | |
| Chris Myer | INVO Bioscience | N/A | |
| Sanjay Ahuja | Tivic Health Systems | N/A | |
| Robert Moccia | STRATA Skin Sciences | 65 | |
| Sam Park | Sight Sciences | 63 | |
| John Liu | Sight Sciences | N/A | |
| MBA BS | Sight Sciences | N/A | |
| Shunichi Kuroda | Bone Biologics Corp | N/A | |
| Kevin Vance | Bluejay Diagnostics | 66 | |
| Keith Simeone | STRATA Skin Sciences | N/A | |
Management Performance
| Return On Equity | 0.3 | ||||
| Return On Asset | 0.0661 |
Bruker Leadership Team
Elected by the shareholders, the Bruker's board of directors comprises two types of representatives: Bruker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bruker. The board's role is to monitor Bruker's management team and ensure that shareholders' interests are well served. Bruker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bruker's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Laukien, Chairman, CEO and Pres | ||
| Burkhard Prause, President and CEO, BEST | ||
| Collin DSilva, Pres Division | ||
| Gerald Herman, Interim CFO, Principal Accounting Officer | ||
| Juergen Srega, President of Bruker Daltonics Division and President of Bruker Calid Group | ||
| Falko Busse, President of the Bruker BioSpin Group and Executive Officer of the Company | ||
| Urban Faeh, Pres GmbH | ||
| Justin Ward, Senior Development | ||
| Stacey Desrochers, Treasurer Relations | ||
| Mark Munch, President of Bruker Nano Group | ||
| Brent JD, General Secretary |
Bruker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bruker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.3 | ||||
| Return On Asset | 0.0661 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.11 % | ||||
| Current Valuation | 12.39 B | ||||
| Shares Outstanding | 145.34 M | ||||
| Shares Owned By Insiders | 33.17 % | ||||
| Shares Owned By Institutions | 77.49 % | ||||
| Number Of Shares Shorted | 4.1 M | ||||
| Price To Earning | 67.10 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bruker. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. To learn how to invest in Bruker Stock, please use our How to Invest in Bruker guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Bruker Stock analysis
When running Bruker's price analysis, check to measure Bruker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bruker is operating at the current time. Most of Bruker's value examination focuses on studying past and present price action to predict the probability of Bruker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bruker's price. Additionally, you may evaluate how the addition of Bruker to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Bruker's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bruker. If investors know Bruker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bruker listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Dividend Share 0.2 | Earnings Share 2.73 | Revenue Per Share 20.554 | Quarterly Revenue Growth 0.053 |
The market value of Bruker is measured differently than its book value, which is the value of Bruker that is recorded on the company's balance sheet. Investors also form their own opinion of Bruker's value that differs from its market value or its book value, called intrinsic value, which is Bruker's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bruker's market value can be influenced by many factors that don't directly affect Bruker's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bruker's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bruker is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bruker's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.